Oxford Nanopore (ONT): What to expect after stellar listing?

October 01, 2021 10:29 AM BST | By Suhita Poddar
Follow us on Google News:


  • UK based biotech firm Oxford Nanopore Technologies made a stellar listing on the LSE main market on 30 September
  • The company became one of the best IPO debuts on the LSE
  • Oxford Nanopore’s H1 2021 revenues were up by 22 per cent to £59.0 million

UK based DNA sequencing biotechnology firm Oxford Nanopore Technologies PLC’s (LON: ONT) shares surged on listing on the LSE on Thursday, making it one of the best IPO debuts on the exchange.

The company’s shares rose by over 45 per cent upon listing. The stocks have extended the momentum on the second day, up by around 2 per cent on Friday’s morning session, trading at GBX 622.30.

Oxford Nanopore’s IPO details

The company’s IPO listing price was at 425 pence per share. This gave the company a market valuation of £3.4 billion. The firm’s IPO price range was between GBX 375 and GBX 450.

Oxford Nanopore raised about £330.1 million in net proceeds through the issue of 123.3 million shares in the IPO. IP Group PLC raised about £84 million from the partial sale of shares in Oxford Nanopore. Now IP group holds 10.3 per cent of shares of the company, following the sale.

Oxford Nanopore plans to use the proceeds to increase its investment in research and development in order to deliver its product pipeline as well to help boost its commercial team by twice its current size over the next 1.5 years.

The company also aims to use the funds to increase its investment in manufacturing automation, customer acquisition initiatives in the medium term, as well as other areas.

Oxford Nanopore Technologies PLC’s (LON: ONT) share price performance

Oxford Nanopore’s shares were trading at GBX 623.70, up by 1.81 per cent on its second day of trading on 1 October at 09:23 AM BST. Unconditional trading of shares is expected to start from 5 October.

Oxford Nanopore’s H1 2021 financial performance

The company’s H1 2021 revenues were up by 22 per cent to £59.0 million, compared to £48.3 million in H1 2020, which it disclosed in its IPO prospectus.

Also, the company reported a net loss of £44.8 million, compared to a loss of £35.5 million in the year before. Oxford’s research and development expenses were up by 29 per cent to £30.6 million, compared to £23.8 million in H1 2020.

Additionally, the company’s selling, general and administrative expenses (SG&A) rose by 28 per cent to £43.2 million, compared to £34.0 million in the year-ago period.


Oxford Nanopore has now become the only UK-based biotech company listed on LSE’s main market so far in 2021. This year, 4 other biotech firms were listed on LSE’s submarket, the Alternative Investment Market (AIM), while four got listed on US’ NASDAQ.

The company had helped in supplying covid-19 testing kits to the UK government and was involved in the gene sequencing of the virus, which helped boost the firm’s performance during the pandemic.

The company’s senior management now aims to expand into cancer diagnostics and eventually look at Oxford Nanopore offerings to have applications in other sectors such as agriculture and farming as well.


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Top LSE Listed Companies